RetinalGenix Technologies (RTGN) Other Non-Current Liabilities (2022 - 2026)
RetinalGenix Technologies (RTGN) reported Other Non-Current Liabilities of $831000.0 for Q1 2026, up 63.99% on a YoY basis from $506748.0 in Q1 2025, and up 69.86% sequentially from $489224.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 5 years of Other Non-Current Liabilities data on file, last reported at $831000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 63.99% year-over-year to $831000.0; the trailing twelve-month figure through Mar 2026 stood at $831000.0 (up 63.99% YoY), and the FY2025 full-year result was $489224.0, up 4.58% from the prior year.
- Other Non-Current Liabilities improved to $831000.0 in Q1 2026, from $489224.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $831000.0 in Q1 2026 to a low of $900.0 in Q3 2023.
- A 5-year average of $425499.0 and a median of $477126.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- Peak annual rise in Other Non-Current Liabilities reached 52914.0% in 2024, while the deepest fall reached 33.05% in 2024.
- Tracing RTGN's Other Non-Current Liabilities over 5 years: stood at $109185.0 in 2022, then jumped by 319.04% to $457534.0 in 2023, then climbed by 2.24% to $467793.0 in 2024, then advanced by 4.58% to $489224.0 in 2025, then soared by 69.86% to $831000.0 in 2026.
- Business Quant data shows RTGN's Other Non-Current Liabilities at $831000.0 in Q1 2026, $489224.0 in Q4 2025, and $539000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 831,000.00 |
| Dec 31, 2025 | 489,224.00 |
| Sep 30, 2025 | 539,000.00 |
| Jun 30, 2025 | 547,148.00 |
| Mar 31, 2025 | 506,748.00 |
| Dec 31, 2024 | 467,793.00 |
| Sep 30, 2024 | 477,126.00 |
| Jun 30, 2024 | 543,061.00 |
| Mar 31, 2024 | 193,000.00 |
| Dec 31, 2023 | 457,534.00 |
| Sep 30, 2023 | 900.00 |
| Jun 30, 2023 | 811,176.00 |
| Mar 31, 2023 | 194,192.00 |
| Dec 31, 2022 | 109,185.00 |
| Jun 30, 2022 | 215,398.00 |